Literature DB >> 12473600

Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.

Nicole J McCarthy1, Xiaowei Yang, Ilona R Linnoila, Maria J Merino, Stephen M Hewitt, Allyson L Parr, Soonmyung Paik, Seth M Steinberg, Dan P Hartmann, Nejib Mourali, Paul H Levine, Sandra M Swain.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: The purpose is to define intratumoral microvessel density (MVD) and potential biological markers that correlate with inflammatory breast cancer (IBC), we examined MVD, estrogen receptor a (ER) status, MIB-1 proliferation index, p53, and c-erbB-2 by immunohistochemistry in archival specimens from 67 women diagnosed with breast cancer with or without the inflammatory phenotype at the Institut Salah Azaiz (Tunis, Tunisia).
RESULTS: The moderate (25-50/x400 field) to high microvessel count (>50/x400 field) was observed in 23 (51%) of 45 IBC tumors compared with 3 (14%) of 22 non-IBC tumors (P = 0.0031; chi(2) test). The presence of ER was found in 6 (14%) of 44 cases versus 7 (32%) of 22 cases in IBC and non-IBC, respectively (P = 0.10). In this series of 67 patient tumors, the median MVD count in ER-negative breast tumors was 21, whereas the median count was 4 in ER-positive breast tumors (P = 0.08; Wilcoxon rank-sum test). However, MIB-1, p53, and c-erbB-2 were not significantly different between IBC and non-IBC tumors. The intratumoral MVD between IBC and non-IBC was still statistically significant after adjustment for multiple comparisons (P = 0.02; Bonferroni test).
CONCLUSIONS: These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473600

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Authors:  Maher A Sughayer; Maha M Al-Khawaja; Suleiman Massarweh; Mahmoud Al-Masri
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

Review 2.  Dioxin may promote inflammation-related development of endometriosis.

Authors:  Kaylon L Bruner-Tran; Grant R Yeaman; Marta A Crispens; Toshio M Igarashi; Kevin G Osteen
Journal:  Fertil Steril       Date:  2008-04-18       Impact factor: 7.329

3.  Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.

Authors:  Hirofumi Asakura; Hitoshi Takashima; Masahiro Mitani; Reiji Haba; Reiko Seo; Koiku Yokoe; Yoshihiro Toyama; Motoomi Ohkawa
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

4.  Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.

Authors:  Amanda Valeta-Magara; Abhilash Gadi; Viviana Volta; Beth Walters; Rezina Arju; Shah Giashuddin; Hua Zhong; Robert J Schneider
Journal:  Cancer Res       Date:  2019-05-01       Impact factor: 12.701

5.  Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Carole Tarpin; Mark Diebel; Benjamin Esterni; Gilles Houvenaeghel; Jean-Marc Extra; François Bertucci; Jocelyne Jacquemier; Luc Xerri; Gabriela Dontu; Giorgio Stassi; Yi Xiao; Sanford H Barsky; Daniel Birnbaum; Patrice Viens; Max S Wicha
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

6.  Experimental endometriosis in immunocompromised mice after adoptive transfer of human leukocytes.

Authors:  Kaylon L Bruner-Tran; Alessandra C Carvalho-Macedo; Antoni J Duleba; Marta A Crispens; Kevin G Osteen
Journal:  Fertil Steril       Date:  2009-07-15       Impact factor: 7.329

7.  TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.

Authors:  Elisa Rossi; Vincenzo Villanacci; Gabrio Bassotti; Francesco Donato; Andrea Festa; Gianpaolo Cengia; Salvatore Grisanti; Renzo Cestari
Journal:  Histopathology       Date:  2010-06-16       Impact factor: 5.087

8.  Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.

Authors:  Sherry X Yang; Seth M Steinberg; Dat Nguyen; Thomas D Wu; Zora Modrusan; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

9.  Prognostic significance of HER-2 status in women with inflammatory breast cancer.

Authors:  Shaheenah Dawood; Kristine Broglio; Yun Gong; Wei-Tse Yang; Massimo Cristofanilli; Shu-Wan Kau; Funda Meric-Bernstam; Thomas A Buchholz; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

10.  The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

Authors:  J Lemieux; M Clemons; L Provencher; S Dent; J Latreille; J Mackey; K I Pritchard; D Rayson; Sh Verma; Su Verma; B Wang; S Chia
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.